160
Participants
Start Date
July 31, 2009
Primary Completion Date
December 31, 2013
Study Completion Date
December 31, 2013
ACC-001+ QS21 (3mcg)
ACC-001 3mcg + QS-21 50 mcg Intra-muscular (IM) q 6 mo
ACC-001 (10 mcg) + QS-21
ACC-001 10mcg + QS-21 50 mcg Intra-muscular (IM) q 6 mo
ACC-001+QS-21 (30mcg)
ACC-001 30mcg + QS-21 50 mcg Intra-muscular (IM) q 6 mo
Columbia University/Taub Institute, New York
CUMC Research Pharmacy, New York
General Clinical Research Unit, Washington D.C.
Georgetown University Medical Center, Washington D.C.
MD Clinical, Hallandale
Palm Beach Neurology - Premiere Research Institute, West Palm Beach
Barnes Jewish Hospital, St Louis
Washington University School of Medicine, St Louis
Barnes Jewish Hospital at Washington University, St Louis
Washington University School of Medicine, St Louis
Banner Alzheimer's Institute, Phoenix
Banner Boswell Medical Center, Sun City
Banner Sun Health Research Institute, Sun City
University of California San Francisco, San Francisco
University of California, San Francisco, San Francisco
University of California - San Francisco, San Francisco
University of California San Francisco, San Francisco
University of California, San Francisco, San Francisco
Yale New Haven Hospital, New Haven
Yale University School of Medicine, New Haven
Yale-New Haven Hospital, New Haven
Brigham and Woman's Hospital, Boston
Center for Alzheimer Research and Treatment, Boston
Memory Enhancement Center of America, Inc., Eatontown
Butler Hospital, Providence
Southwestern Vermont Healthcare, Bennington
The Memory Clinic, Bennington
The Pharmacy, Inc, Bennington
Lead Sponsor
JANSSEN Alzheimer Immunotherapy Research & Development, LLC
INDUSTRY
Pfizer
INDUSTRY